Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition

F. Stocchi, L. Vacca, P. Grassini, M. F. De Pandis, G. Battaglia, C. Cattaneo, R. G. Fariello

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

In an open pilot study, doses of safinamide (100, 150, and 200 mg once a day, higher than previously tested) were administered to 13 parkinsonian patients along with a stable dose of dopamine (DA) agonist, causing a significant progressive improvement in motor performance as evaluated by the Unified Parkinson Disease Rating Scale (UPDRS) part III over an 8-week period (4.2 points; P <0.001). In association with levodopa, the same doses of safinamide in another group of patients (N = 11) induced a significant decrease in motor fluctuations (UPDRS part IV, 2.1 points; P <0.001), accompanied by a dose-proportional increase of the levodopa AUC, up to 77% from baseline. Because MAO-B was fully inhibited (95%) at all doses tested, we suggest that these biochemical and symptomatic dose-dependent effects must be related to additional mechanisms of action, such as inhibition of glutamate release, increased dopamine release, or inhibition of dopamine re-uptake. These hypotheses are under investigation and will pursue confirmation in controlled clinical trials.

Original languageEnglish
JournalNeurology
Volume67
Issue number7 SUPPL. 2
Publication statusPublished - Oct 2006

Fingerprint

Monoamine Oxidase
Levodopa
Parkinson Disease
Dopamine
Dopamine Agonists
Controlled Clinical Trials
Area Under Curve
Glutamic Acid
safinamide

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Symptom relief in Parkinson disease by safinamide : Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. / Stocchi, F.; Vacca, L.; Grassini, P.; De Pandis, M. F.; Battaglia, G.; Cattaneo, C.; Fariello, R. G.

In: Neurology, Vol. 67, No. 7 SUPPL. 2, 10.2006.

Research output: Contribution to journalArticle

@article{ddfa272f89dd43b7ace92b286362c735,
title = "Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition",
abstract = "In an open pilot study, doses of safinamide (100, 150, and 200 mg once a day, higher than previously tested) were administered to 13 parkinsonian patients along with a stable dose of dopamine (DA) agonist, causing a significant progressive improvement in motor performance as evaluated by the Unified Parkinson Disease Rating Scale (UPDRS) part III over an 8-week period (4.2 points; P <0.001). In association with levodopa, the same doses of safinamide in another group of patients (N = 11) induced a significant decrease in motor fluctuations (UPDRS part IV, 2.1 points; P <0.001), accompanied by a dose-proportional increase of the levodopa AUC, up to 77{\%} from baseline. Because MAO-B was fully inhibited (95{\%}) at all doses tested, we suggest that these biochemical and symptomatic dose-dependent effects must be related to additional mechanisms of action, such as inhibition of glutamate release, increased dopamine release, or inhibition of dopamine re-uptake. These hypotheses are under investigation and will pursue confirmation in controlled clinical trials.",
author = "F. Stocchi and L. Vacca and P. Grassini and {De Pandis}, {M. F.} and G. Battaglia and C. Cattaneo and Fariello, {R. G.}",
year = "2006",
month = "10",
language = "English",
volume = "67",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7 SUPPL. 2",

}

TY - JOUR

T1 - Symptom relief in Parkinson disease by safinamide

T2 - Biochemical and clinical evidence of efficacy beyond MAO-B inhibition

AU - Stocchi, F.

AU - Vacca, L.

AU - Grassini, P.

AU - De Pandis, M. F.

AU - Battaglia, G.

AU - Cattaneo, C.

AU - Fariello, R. G.

PY - 2006/10

Y1 - 2006/10

N2 - In an open pilot study, doses of safinamide (100, 150, and 200 mg once a day, higher than previously tested) were administered to 13 parkinsonian patients along with a stable dose of dopamine (DA) agonist, causing a significant progressive improvement in motor performance as evaluated by the Unified Parkinson Disease Rating Scale (UPDRS) part III over an 8-week period (4.2 points; P <0.001). In association with levodopa, the same doses of safinamide in another group of patients (N = 11) induced a significant decrease in motor fluctuations (UPDRS part IV, 2.1 points; P <0.001), accompanied by a dose-proportional increase of the levodopa AUC, up to 77% from baseline. Because MAO-B was fully inhibited (95%) at all doses tested, we suggest that these biochemical and symptomatic dose-dependent effects must be related to additional mechanisms of action, such as inhibition of glutamate release, increased dopamine release, or inhibition of dopamine re-uptake. These hypotheses are under investigation and will pursue confirmation in controlled clinical trials.

AB - In an open pilot study, doses of safinamide (100, 150, and 200 mg once a day, higher than previously tested) were administered to 13 parkinsonian patients along with a stable dose of dopamine (DA) agonist, causing a significant progressive improvement in motor performance as evaluated by the Unified Parkinson Disease Rating Scale (UPDRS) part III over an 8-week period (4.2 points; P <0.001). In association with levodopa, the same doses of safinamide in another group of patients (N = 11) induced a significant decrease in motor fluctuations (UPDRS part IV, 2.1 points; P <0.001), accompanied by a dose-proportional increase of the levodopa AUC, up to 77% from baseline. Because MAO-B was fully inhibited (95%) at all doses tested, we suggest that these biochemical and symptomatic dose-dependent effects must be related to additional mechanisms of action, such as inhibition of glutamate release, increased dopamine release, or inhibition of dopamine re-uptake. These hypotheses are under investigation and will pursue confirmation in controlled clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=33750000049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750000049&partnerID=8YFLogxK

M3 - Article

C2 - 17030737

AN - SCOPUS:33750000049

VL - 67

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7 SUPPL. 2

ER -